Factor XI and the Critical Difference Between Inhibiting Thrombosis and Inhibiting Hemostasis

Oct 27, 2021 | Antithrombotics

2) This series is supported by educational grants from Bayer & AstraZeneca & is intended for healthcare professionals. Faculty disclosures & statement of accreditation at https://t.co/gvXca4G9Xm. Earlier programs, still available for credit, are at...

Management of Hyperkalemia in Patients Treated with RAASi/MRAs

Aug 25, 2021 | HYPERKALEMIA

2) This program is intended for healthcare professionals and is supported by educational grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk. See archived programs, all by expert authors, still available for credit at https://t.co/U6Mo1oSwIh— cardio-met...

Initiating New Anti-thrombotic Therapy into the Treatment Regimen of a Patient with PAD

Mar 11, 2021 | PAD

2) Accredited for 0.5 credits by @academiccme: physicians, nurses, pharmacists! Expert faculty @dlbhattmd. Supported by Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. Follow this thread for credit. #cardiotwitter #medtwitter— cardio-met (@cardiomet_CE) March 8, 2021...

The Effects of Dapagliflozin on Worsening Heart Failure

Mar 1, 2021 | CARDIORENAL

Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @mkosiborodmd #medtwitter @academiccme #cardiotwitter— cardio-met (@cardiomet_CE) February 25, 2021 2) Accredited for 0.5 credits by @academiccme: physicians, nurses, pharmacists! Expert faculty...

New-Generation Potassium Binders to Facilitate Guidelines-Based RAASi Therapy

Feb 12, 2021 | HYPERKALEMIA

This activity is supported by educational grants from Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. In case you missed the tweetorial on Twitter “real time” you can review the course material here and earn the same credit. 2) . . . Supported by Abbott, AstraZeneca,...